I think it was no coincidence that the FDA denied the mitochondrial citizen petition during the same time frame that they approved label changes. Right now the FDA is not acknowledging even the risk of mitochondrial toxicity.
On Thursday May 12, 2016 the FDA contacted those who have been pursuing label changes for the Fluoroquinolones and issued a public statement that the FDA is requiring label changes for antibacterial drugs called fluoroquinolones
Dr. Charles Bennett has been able to successfully publish a paper titled “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.”
It is very disturbing that an antibiotic, which is often given out for routine infections, may result in violence, anger toward others, and horribly, may result in suicide-related adverse events.
On Nov. 5th, the true stars of our community took to the podium at the FDA to tell their personal stories. I, along with countless others, were humbled and honored. This meeting represented a huge step in the progress we are making to gain complete recognition of the travesty that the fluoroquinolone class of pharmaceuticals has wrought upon society, to achieve justice for those that have been damaged by these drugs, and to prevent future unnecessary pain and suffering not only for this generation, but for generations to come.
A interesting two part series covering our five year research relationship with Dr. Noble, U of R; In this article, part 2, he reveals troubling findings about Levaquin.
A interesting two part series covering our five year research relationship with Dr. Noble, U of R; He has assisted us with a submission for the upcoming FDA Meeting, asked us to collect data for his research, and in part 2 reveals troubling findings about Levaquin.
Dr. Beatrice Golomb, University of California San Diego, has been able to successfully publish a paper with four case reports of individuals suffering from Fluoroquinolone Toxicity.
We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.
On August 24th, 2015, members from the FQ community met with staff from the FDA in a third meeting to address the various FDA failures to adequately warn the general public about the true dangers FQ’s pose to the general public, especially our children.
Dr. Miriam J. de Jonge M.D., who herself was floxed has contacted me and asked me to post, what I feel, is a comprehensive and well documented “Dear Colleague” letter, informing other doctors of (FQ) toxicity. It can be used to foster patient/doctor discussions. It is available here to download.
Please help support our fundraising t-shirt campaign, which will provide visual awareness to the eyes of the world, and assist us with operating costs. We have designed a t-shirt to help bring FQ awareness to the general public, but this cannot happen without your assistance.
Why would the FDA make such an outrageous decision to enter into an unprecedented agreement to monitor post-marketing drug surveillance with a private company run by ex-pharmaceutical executives? The FDA would be better off looking at its FAERS data. If they did, they would see drug signals that they have ignored, especially for FQ’s.